Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Gains 5%; BSE HEALTHCARE Index Down 0.2%
Tue, 17 Sep 10:57

Panacea Biotech Gains 5%; BSE HEALTHCARE Index Down 0.2%Image source: Eoneren/www.istockphoto.com

Panacea Biotech share price has zoomed 5% and is presently trading at Rs 349.6.

Meanwhile, the BSE HEALTHCARE index is at 44,289.3 (down 0.2%).

Among the top gainers in the BSE HEALTHCARE index today are ALEMBIC PHARMA (up 1.6%) and Divis Laboratories (up 1.0%).

Biocon (down 2.4%) and KIMS (down 2.2%) are among the top losers today.

Over the last one year, Panacea Biotech has moved up from Rs 133.3 to Rs 349.6, registering a gain of Rs 216.3 (up 162.3%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,434.4 to 44,289.3, registering a gain of 55.8% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 172.8%), SUVEN PHARMACEUTICALS (up 124.0%) and Glenmark Pharma (up 100.7%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 82,984.8 .

The top losers among the BSE Sensex today are Tata Motors (down 2.1%) and MUNDRA PORT & SEZ (down 1.1%). The most traded stocks in the BSE Sensex are Tata Motors and Tata Steel.

In the meantime, NSE Nifty is at 25,412.3 (up 0.1%). Hero Motocorp and Divis Laboratories are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 67,467.0 to 82,984.8, registering a gain of 15,517.8 points (up 23.0%).

Panacea Biotech Financial Update...

Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.

For the year ended March 2023, Panacea Biotech reported 103.1% decrease in net profit to Rs -337 million compared to net profit of Rs 10,783 million during FY22. Revenue of the company fell 30.4% to Rs 4,599 million during FY23.

The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -75.5.


Equitymaster requests your view! Post a comment on "Panacea Biotech Gains 5%; BSE HEALTHCARE Index Down 0.2%". Click here!